Results from the DELTA FORCE study, a phase III trial, demonstrated the superior efficacy and safety of delgocitinib cream over oral alitretinoin in adult patients with severe chronic hand eczema. Delgocitinib cream showed significantly greater reduction in Hand Eczema Severity Index scores, higher improvement in Investigator’s Global Assessment, relief from itch and pain, and better quality of life compared to alitretinoin. The study suggests delgocitinib cream as a potential nonsystemic treatment alternative for this condition.

Source: The Lancet